Alembic's generic Pristiq, which is indicated for the treatment of major depressive disorder, had a market value of approximately $13.3 million, according to IQVIA.
Alok Sonig, the former CEO of developed markets at Dr. Reddy's, has been named the new CEO of Lupin's U.S. generics and global head generics R&D and biosimilars.
Mylan is introducing the first generic of Baxter’s Brevibloc injection, which had a market value of approximately $126 million for the 12 months ending June 30, according to IQVIA.
The FDA has published 54 product-specific guidances, including 42 new guidances and 12 revised guidances that when finalized will show its expectations on how to develop generic drug products.